全身AMPK活性化剤MK-8722は,グルコースホメオスタシスを改善するが,心筋縮を誘発する
Robert W Myers1, Hong-Ping Guan2, Juliann Ehrhart3
1In Vitro Pharmacology, Merck Research Laboratories, Kenilworth, NJ 07033, USA. robertwmyersphd@gmail.com iyassu@kallyope.com.
まとめ
新しい薬であるMK-8722は,5'-アデノシンモノフォスファート活性化タンパク質キナーゼ (AMPK) を活性化し,グルコースの吸収と合成を改善します. 低血糖を引き起こすことなく,代謝の調節を約束しています.
科学分野:
- 生物化学
- 代謝の調節
- 薬理学について
背景:
- 5 - アデノシンモノフォスファート活性化タンパク質キナーゼ (AMPK) は,エネルギーホメオスタシスにとって極めて重要です.
- AMPKの役割と治療の可能性の理解は,効果的な薬理学的手段の欠如によって制限されています.
研究 の 目的:
- 哺乳類の12のAMPK複合体の新規活性化剤を開発し,特徴づけること.
- AMPKの活性化による生理学的効果を in vivoで調査する.
主な方法:
- 直接的アロステリックAMPK活性化剤であるMK-8722の開発
- MK-8722をネズミとレサス猿 (糖尿病モデルを含む) に投与する.
- グルコースの吸収,グリコゲンの合成,血糖値,心臓のパラメータの評価
主要な成果:
- MK-8722は骨格筋におけるAMPKを強力に活性化させ,インスリンに依存しないグルコース吸収とグリコゲン合成につながった.
- 血糖値の有意な改善は,低血糖症なしで観察されました.
- 心臓高縮症と心臓のグリコゲンの増加は認められたが,明らかに機能的な問題はない.
結論:
- MK-8722は強力なAMPK活性化剤で,代謝障害の治療の可能性があります.
- AMPKの活性化により,インスリンとは無関係に血糖値を下げることができます.
- 長期にわたるMK-8722治療の心臓への影響を完全に理解するには,さらなる研究が必要です.
関連する概念動画
cAMP-dependent Protein Kinase Pathways
8.7K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.7K
PI3K/mTOR/AKT Signaling Pathway
5.8K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.8K
Global Regulatory Systems
783
Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
783
GPCRs Regulate Adenylyl Cylase Activity
7.8K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.8K
Oral Hypoglycemic Agents: Biguanides and Glitazones
732
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
732
Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K


